Lancashire (LRE) Competitors

Mediclinic International (LON:MDC) and Lancashire (LON:LRE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.

Do analysts prefer MDC or LRE?

Lancashire has a consensus price target of GBX 781, suggesting a potential upside of 23.19%. Given Lancashire's higher possible upside, analysts plainly believe Lancashire is more favorable than Mediclinic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mediclinic International	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Lancashire	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Which has more volatility and risk, MDC or LRE?

Mediclinic International has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Lancashire has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

Does the media prefer MDC or LRE?

In the previous week, Lancashire had 1 more articles in the media than Mediclinic International. MarketBeat recorded 1 mentions for Lancashire and 0 mentions for Mediclinic International. Mediclinic International's average media sentiment score of 0.75 equaled Lancashire'saverage media sentiment score.

Company	Overall Sentiment
Mediclinic International	Positive
Lancashire	Positive

Is MDC or LRE a better dividend stock?

Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays an annual dividend of GBX 18 per share and has a dividend yield of 2.8%. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Lancashire pays out 1,592.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Is MDC or LRE more profitable?

Lancashire has a net margin of 26.72% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 23.96% beat Mediclinic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mediclinic International	4.99%	5.50%	2.30%
Lancashire	26.72%	23.96%	6.75%

Do institutionals and insiders believe in MDC or LRE?

39.2% of Mediclinic International shares are owned by institutional investors. Comparatively, 60.5% of Lancashire shares are owned by institutional investors. 48.9% of Mediclinic International shares are owned by company insiders. Comparatively, 0.6% of Lancashire shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer MDC or LRE?

Lancashire received 115 more outperform votes than Mediclinic International when rated by MarketBeat users. However, 57.33% of users gave Mediclinic International an outperform vote while only 44.53% of users gave Lancashire an outperform vote.

Company	Underperform	Outperform
Mediclinic International	Outperform Votes 219 57.33%	Underperform Votes 163 42.67%
Lancashire	Outperform Votes 334 44.53%	Underperform Votes 416 55.47%

Which has better earnings & valuation, MDC or LRE?

Lancashire has lower revenue, but higher earnings than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mediclinic International	£3.38B	0.00	£169M	£0.23	N/A
Lancashire	£1.36B	1.12	£363.10M	£1.13	561.06

Summary

Lancashire beats Mediclinic International on 12 of the 17 factors compared between the two stocks.